Sigachi Industries DuPont analysis

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.12×0.94×0.76×0.82×0.80×
0.81×−2.42×1.10×1.06×1.05×
6.1%7.6%17.2%16.5%17.2%
0.57×0.57×0.63×0.75×0.81×
1.59×1.59×1.38×1.57×1.39×
5.1%−15.7%12.5%16.9%16.3%
−14.6%−14.6%13.5%16.4%16.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SIGACHI₹26.60

Sigachi Industries Limited

· Pharma & Health
₹ CrorePeersLINCOLNTHEMISMEDBAJAJHCAREAMRUTANJANJAGSNPHARMWANBURYNGLFINEMcap ₹1,016 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.800.820.760.941.12
Interest Burden (Pretax/EBIT) ×1.051.061.10-2.420.81
EBIT Margin %17.2516.5117.257.576.14
Asset Turnover ×0.810.750.630.570.57
Financial Leverage (Assets/Equity) ×1.391.571.381.591.59
ROE (5-step product, year-end total equity) %16.2616.9412.55-15.715.07
ROE (owners' profit / average owners' equity) %16.2216.3813.50-14.57-14.57
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.